TherapeuticsMD Inc (TXMD) Sees Unusually-High Trading Volume
TherapeuticsMD Inc (NASDAQ:TXMD) shares saw unusually-strong trading volume on Tuesday . Approximately 1,286,677 shares changed hands during mid-day trading, an increase of 5% from the previous session’s volume of 1,229,857 shares.The stock last traded at $6.65 and had previously closed at $6.67.
A number of research analysts have commented on TXMD shares. Noble Financial reaffirmed a “buy” rating and issued a $17.50 target price on shares of TherapeuticsMD in a research report on Monday, July 11th. Jefferies Group reaffirmed a “buy” rating on shares of TherapeuticsMD in a research report on Wednesday, June 8th. Finally, Zacks Investment Research raised shares of TherapeuticsMD from a “sell” rating to a “hold” rating in a research report on Tuesday, September 13th.
The stock has a 50 day moving average of $7.07 and a 200 day moving average of $7.67. The firm’s market cap is $1.29 billion.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/20/therapeuticsmd-inc-txmd-sees-unusually-high-trading-volume.html
TherapeuticsMD (NASDAQ:TXMD) last released its quarterly earnings results on Thursday, August 4th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.10) by $0.01. The firm earned $4.40 million during the quarter, compared to analyst estimates of $5.63 million. The firm’s revenue was down 8.3% on a year-over-year basis. During the same period in the previous year, the business earned ($0.16) earnings per share. Equities analysts expect that TherapeuticsMD Inc will post ($0.43) EPS for the current fiscal year.
TherapeuticsMD Company Profile
TherapeuticsMD, Inc is a women’s healthcare product company. The Company’s segment is creating and commercializing products for women. It is focused on conducting clinical trials necessary for regulatory approval and commercialization of advanced hormone therapy pharmaceutical products. Its drug candidates are created using its SYMBODA hormone technology, which enables the administration of hormones with high bioavailability alone or in combination.
Receive News & Ratings for TherapeuticsMD Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD Inc and related companies with MarketBeat.com's FREE daily email newsletter.